poisar

Stocks · News reference

This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's analyst ratings page. See analyst views on ICUI, BDSX,.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AVTXBDSXCEVAESEFRVOICUIKDPLCLN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  3. Benzinga Newsdesk

    Avalo Therapeutics Q2 EPS $(0.83) Misses $(0.58) Estimate

    Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.58) by 43.1 percent. This is a 56.77 percent increase over losses of $(1.92) per share

    AVTX
  5. Not Specified

    Biodesix to Participate in Upcoming Investor Conferences

    Biodesix, Inc. announced its participation in three upcoming investor conferences in September 2026. The company reported Q2 2026 revenue of $26.9 million, representing 34% growth, with an 82% gross margin. Biodesix maintained its FY 2026 revenue guidance of $108-114 million, reflecting 25% growth expectations.

    BDSX